bone, as well as in distant bones (Figure 2d ). The graft also increased over time, implying that the cells were expanding in the mice. Thus, NSGS mice offer the opportunity to perform xenotransplant studies for these pre-leukemic myeloid cells.
Genomic imprinting is an epigenetic phenomenon that ensures the parental-specific expression of a subset of genes and is required for the normal mammalian development.
Loss of genomic imprinting represents one of the most common genetic abnormalities in growth disorders and cancer. DNA methylation is a key component of genomic imprinting regulation in eutherian mammals, and most imprinted genes are associated with differentially methylated CpG-rich regions.
Delta-like homolog 1 (Dlk1) is an exclusively paternally expressed gene that encodes an epidermal growth factor-like transmembrane protein with homology to members of the Notch/Delta/Serrate family. Knockout mice, which are deficient in Dlk1, exhibit perturbations in megakaryocyte and B cell development. 1 The role of Dlk1 in leukemogenesis is unclear as enforced overexpression of Dlk1 elicits opposing effects on proliferation in a cell-context-dependent manner.
1,2 Nevertheless, the importance of DLK1 is underscored by its frequent overexpression in myelodysplastic syndrome and acute myeloid leukemia (AML) patient samples. 1 More recently, Khoury et al. 3 have demonstrated that a high proportion of AML samples overexpressing DLK1 exhibited biallelic expression of DLK1 with concomitant DNA hypermethylation of associated CpGrich regions within the imprinting control regions. We have previously demonstrated that Dlk1 is directly and robustly induced in response to the overexpression of proto-oncogene Meis1 in a NUP98-HOXD13 (ND13) AML murine model. 4 MEIS1 is a critical regulator of normal and leukemic stem cells and is a potent collaborative gene that is frequently deregulated in human AML and acute lymphoid leukemia samples, in which high expression is correlated with poor prognosis. 5 To investigate whether overexpression of Dlk1 in the ND13 model results from Meis1-induced alterations in the imprinting status of Dlk1, bone marrow (BM) from the congenic mouse strains C57BL/6Ly, DBA/2J and their F 1 progeny were transduced with retroviral vectors were engineered to overexpress ND13 marked with green fluorescent protein (ND13-GFP), Meis1 marked with yellow fluorescent protein (Meis1-YFP) or a combination of ND13-GFP with Meis1-YFP or ND13-GFP with Meis1DHD-YFP (encoding a DNA-binding defective Meis1 hypomorph) as previously described. 4 Appropriately transduced BM cells were isolated by fluorescence-activated cell sorting and subjected to complementary DNA synthesis as previously described. 4 Semiquantitative PCR revealed that maximal induction of Dlk1 expression was codependent on ND13 and Meis1, as its expression was not detected in unmanipulated parental or F 1 BM or Meis1-transduced BM (Figure 1a) . The PCR amplicons, spanning the intronic single nucleotide polymorphism rs6287933, were gel extracted and sequenced. Although monoallelic paternal expression of Dlk1 was observed in ND13-transduced F 1 BM, biallelic expression was observed in the ND13 þ Meis1-transduced (Figure 1b) . Overexpression of Meis1 in a Hoxa9-immortalized BM cell line did not result in a significant upregulation of Dlk1 levels (data not shown). These results demonstrate that Meis1 cooperates with ND13 to disrupt the genomic imprint of Dlk1, a phenomenon requiring the DNA-binding domain of Meis1.
Dlk1 is linked to the reciprocally imprinted noncoding gene Gene-trap locus 2 (Gtl2). 6 With respect to the genomic structure and the reciprocal imprinting status of Dlk1/Gtl2, this locus is highly reminiscent to the paradigmatic imprinted loci, Igf2 and H19. On the basis of this similarity, Takada et al. 8 identified three differentially methylated regions (DMRs) within the Dlk1/Gtl2 locus that are purported to be the imprinting control centers: the exonic Dlk1-DMR in the 3 0 region of Dlk1, the intergenic DMR (IG-DMR) (75 kb downstream of Dlk1 and 15 kb upstream of Gtl2) and the Gtl2 DMR at the Gtl2 promoter. The IG-DMR was shown to be predominantly hypomethylated on the maternal allele and hypermethylated on the paternal allele. The Dlk1-DMR exhibited tissue-specific differential methylation patterns wherein, in most cases, the paternal allele was more hypermethylated than the maternal allele. However, tissue-specific differential DNA methylation did not correlate to significant changes in gene expression levels. Furthermore, maternal inheritance of a targeted deletion of the IG-DMR resulted in the loss of imprinting of both Dlk1 and Gtl2 as opposed to a paternally inherited deletion, in which the imprinting status was not affected, 7 supporting the role of the IG-DMR as a key imprinting control element for this region. Given these findings, we assessed whether loss of imprinting of the Dlk1 locus in response to the overexpression of Meis1 in the ND13 AML corresponded with alterations of the DNA methylation status of the IG-DMR. In addition, to assess whether binding of Meis1altered the DNA methylation status of a Meis1-associated region, we examined the CpG islands within the Dlk1 promoter previously demonstrated to be bound by Meis1. 4 Interrogation of the DNA methylation status by bisulfite sequencing, performed as previously described, 8 revealed that overexpression of Meis1 significantly increased the level of DNA methylation of the IG-DMR compared with ND13 alone (Figure 2a) . Conversely, overexpression of Meis1 did not alter the DNA methylation status of the Dlk1 promoter compared with ND13 alone. These data indicate that the ability of Meis1, in cooperation with ND13, to perturb the imprinting status of Dlk1 strongly correlates with concomitant DNA hypermethylation of the IG-DMR but not the Dlk1 promoter. The IG-DMR was found not to be associated with Meis1 binding as determined by chromatin immunoprecipitation-Solexa sequencing (BA and RKH, unpublished data). These findings represent a novel, indirect function of Meis1 and may be in line with recent observations showing that constitutive DNA Letters to the Editor methylation is essential for normal and leukemic stem cell self-renewal. 9 In support of this, overexpression of Meis1 in the ND13 AML model resulted in the elevated expression of the DNA methyltransferases Dnmt1a, Dnmt3a and Dnmt3b compared with ND13 BM cells transduced with an empty vector control (ND13 þ MIY), as determined by quantitative PCR (Figure 2b) .
The demonstration that loss of imprinting of DLK1 by DNA hypermethylation is a frequent event in AML underscores its importance in leukemia. However, enforced overexpression of Dlk1 with ND13 was insufficient to induce AML, 4 suggesting that the growth-promoting effects of Dlk1, as documented in the literature, is cell context specific and may be critically dependent on the magnitude of Dlk1 induction. Furthermore, as we were unable to document a positive correlation between MEIS1 and DLK1 expression in all AML patient samples tested (Figure 2b) , we hypothesize that loss of imprinting of DLK1 is a function of specific collaborating genetic events, of which ND13 and Meis1 are the first to be identified.
Dlk1 represents one member of a large cluster of imprinted genes which, to date, includes three coding genes, seven noncoding RNAs and up to 52 miRNAs. 10 The complex interplay between the epigenetic modifications at the imprinting centers, chromatin boundary formation by CCCTC-binding factor and the function of the genes in this region are just being uncovered. Together with Khoury et al. 3 our studies warrant further investigation into the role of dysregulated DLK1 expression in leukemia. It will be important to determine whether the loss of imprinting of DLK1 has a causal role in the initiation or maintenance of select hematologic malignancies or whether it is a benign consequence of the malignant process. Lastly, can this phenomenon be used as a biomarker or prognostic tool for AML and/or can this be exploited as a potential avenue for therapy of AML.
Effects of MSC co-injection on the reconstitution of aplastic anemia patient following hematopoietic stem cell transplantation Immunosuppressive therapy together with hematopoietic stem cell transplantation is used in the management of acquired severe aplastic anemia. However, despite significant improvement in these two treatment modalities, graft failure and graft-versus-host disease still remains the major challenge that needs to be addressed. 1 Mesenchymal stem cells (MSCs) are adult multipotent cells capable of multipotential differentiation that possess immunosuppressive properties and are in use in the clinical setting to treat graft-versus-host disease.
2,3
Because of their fundamental function in maintaining HSC self-renewal and regulating hematopoiesis, MSC have also been used to facilitate donor HSC engraftment. 4 In this study we report our experience with a severe aplastic anemia patient who failed to respond to three allogeneic hematopoietic stem cell transplantation, but after the co-administration of MSC fully recovered a hematopoietic system within 4 weeks
